Literature DB >> 15899746

Propofol: an immunomodulating agent.

Paul E Marik1.   

Abstract

Propofol (2,6-diisopropylphenol) is a potent intravenous hypnotic agent widely administered for induction and maintenance of anesthesia and for sedation in the intensive care unit. Propofol is insoluble in water and therefore is formulated in a lipid emulsion. In addition, a preservative (ethylenediaminetetraacetic acid [EDTA] or sodium metabisulfite) is added to retard bacterial growth. Propofol has antiinflammatory properties, decreasing production of proinflammatory cytokines, altering expression of nitric oxide, and inhibiting neutrophil function. Propofol also is a potent antioxidant. The added preservatives have biologic activity; EDTA has antiinflammatory properties, whereas metabisulfite may cause lipid peroxidation. The antiinflammatory and antioxidant properties of propofol may have beneficial effects in patients with sepsis and systemic inflammatory response syndrome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15899746     DOI: 10.1592/phco.2005.25.5_part_2.28s

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  38 in total

1.  The use of propofol for medium and long-term sedation in critically ill adult patients: a meta-analysis.

Authors:  Kwok M Ho; Joseph Y Ng
Journal:  Intensive Care Med       Date:  2008-06-25       Impact factor: 17.440

2.  Propofol Attenuates Inflammatory Response in LPS-Activated Microglia by Regulating the miR-155/SOCS1 Pathway.

Authors:  Xinxun Zheng; Hongbing Huang; Jianjun Liu; Minghua Li; Min Liu; Tao Luo
Journal:  Inflammation       Date:  2018-02       Impact factor: 4.092

Review 3.  Immunosuppressive aspects of analgesics and sedatives used in mechanically ventilated patients: an underappreciated risk factor for the development of ventilator-associated pneumonia in critically ill patients.

Authors:  Michael A Smith; Maho Hibino; Bonnie A Falcione; Katherine M Eichinger; Ravi Patel; Kerry M Empey
Journal:  Ann Pharmacother       Date:  2013-11-04       Impact factor: 3.154

4.  Probe substrate and enzyme source-dependent inhibition of UDP-glucuronosyltransferase (UGT) 1A9 by wogonin.

Authors:  Gao Chengcheng; Xie Rui; Ma Tianheng; Yan Wei; Pang Liqun
Journal:  Afr Health Sci       Date:  2013-09       Impact factor: 0.927

5.  Propofol Sedation Exacerbates Kidney Pathology and Dissemination of Bacteria during Staphylococcus aureus Bloodstream Infections.

Authors:  Lavanya Visvabharathy; Nancy E Freitag
Journal:  Infect Immun       Date:  2017-06-20       Impact factor: 3.441

6.  Lactate-to-pyruvate ratio as a marker of propofol infusion syndrome after subarachnoid hemorrhage.

Authors:  Jared M Pisapia; Linda C Wendell; Monisha A Kumar; Eric L Zager; Joshua M Levine
Journal:  Neurocrit Care       Date:  2011-08       Impact factor: 3.210

7.  Propofol sedation in total knee replacement : effects on oxidative stress and ischemia-reperfusion damage.

Authors:  D Özkan; T Akkaya; A Yalcindag; T Hanci; E Gönen; H Gümüs; N Delibas
Journal:  Anaesthesist       Date:  2013-06-30       Impact factor: 1.041

8.  Tourniquet-induced ischemia-reperfusion injuries during extremity surgery at children's age: impact of anesthetic chemical structure.

Authors:  Ivana Budic; Dusica Pavlovic; Dusanka Kitic; Gordana Kocic; Tatjana Cvetkovic; Dusica Simic; Tatjana Jevtovic-Stoimenov
Journal:  Redox Rep       Date:  2013       Impact factor: 4.412

Review 9.  Anesthetic modulation of immune reactions mediated by nitric oxide.

Authors:  Noboru Toda; Hiroshi Toda; Yoshio Hatano
Journal:  J Anesth       Date:  2008-05-25       Impact factor: 2.078

10.  Propofol maintains Th17/Treg cell balance and reduces inflammation in rats with traumatic brain injury via the miR‑145‑3p/NFATc2/NF‑κB axis.

Authors:  Can Cui; Dengwen Zhang; Ke Sun; Haifeng Li; Liqian Xu; Gen Lin; Yuanbo Guo; Jiaqi Hu; Jieyuan Chen; Lidan Nong; Yujin Cai; Dongnan Yu; Wei Yang; Peng Wang; Yi Sun
Journal:  Int J Mol Med       Date:  2021-05-26       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.